Last reviewed · How we verify
Rifaximin、Lactulose
At a glance
| Generic name | Rifaximin、Lactulose |
|---|---|
| Sponsor | Air Force Military Medical University, China |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Oedema peripheral
- Constipation
- Nausea
- Fatigue
- Insomnia
- Urinary tract infection
- Pruritus generalised
- Muscle spasms
- Abdominal pain
- Decreased appetite
- Ascites
- Vomiting
Key clinical trials
- Evaluation of the Outcome of Fecal Microbiota Transplantation (PHASE1, PHASE2)
- Efficacy and Safety of Early Initiation of Midodrine for Control and Prevention of Ascites and Its Related Complications in Acute-on-chronic Liver Failure. (NA)
- Hydrogen Breath Test an Instrument to Predict Rifaximin-Response in Irritable Bowel Syndrome Predominant Diarrhea (PHASE4)
- Growth Hormone in Decompensated Liver Cirrhosis (PHASE2, PHASE3)
- Efficacy and Safety of Nifuroxazide in the Treatment of Hepatic Encephalopathy in Egyptian Patients With Liver Cirrhosis (PHASE3)
- Human Albumin Infusion in Liver Cirrhosis and Overt Hepatic Encephalopathy (HACHE) (NA)
- A Trial for Comparing Rifaximin, Probiotic and L-ornithine- L Aspartate With Lactulose in Overt Hepatic Encephalopathy. (PHASE4)
- BCAA vs. Rifaximin in Patients With Cirrhosis for Secondary Prophylaxis of HE (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rifaximin、Lactulose CI brief — competitive landscape report
- Rifaximin、Lactulose updates RSS · CI watch RSS
- Air Force Military Medical University, China portfolio CI